Author： Van Rite Brent D. Krais John J. Cherry Mohamad Sikavitsas Vassilios I. Kurkjian Carla Harrison Roger G.
Publisher： Informa Healthcare
ISSN： 0735-7907
Source： Cancer Investigation, Vol.31, Iss.8, 2013-10, pp. : 505-510
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
The L-methioninase-annexin V/selenomethionine enzyme prodrug system, designed to target the tumor vasculature and release the methylselenol anticancer drug in the tumor, was tested in mice with implanted MBA-MB-231 breast tumors. This therapy was able to cause a reduction in the size of the tumors during the treatment period. It was shown that L-methioninase-annexin V was uniformly bound at the blood vessel surface in the tumor and also that there was a substantial cutoff of blood flowing through the treated tumor, consistent with the therapy's design. This new approach for enzyme prodrug therapy of breast cancer appears promising.
Related content
Access to resources
Recommend
By Lo Kin-Ming Lan Yan Lauder Scott Zhang Jinyang Brunkhorst Beatrice Qin Guozhong Verma Rakesh Courtenay-Luck Nigel Gillies Stephen
Cancer Immunology, Immunotherapy, Vol. 56, Iss. 4, 2007-04 ,pp. :
Abrogation Of Tumor Vasculature Using Gene Therapy
By Nesbit M.
Cancer and Metastasis Reviews, Vol. 19, Iss. 1-2, 2000-06 ,pp. :
By Iankov Ianko Msaouel Pavlos Allen Cory Federspiel Mark Bulur Peggy Dietz Allan Gastineau Dennis Ikeda Yasuhiro Ingle James Russell Stephen Galanis Evanthia
Breast Cancer Research and Treatment, Vol. 122, Iss. 3, 2010-08 ,pp. :